ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1168

Eosinophilic Fasciitis:  Baseline Retrospective Evaluation of Clinical Characteristics and Prognosis in a Cohort of 83 Patients

Robert L. Mango1, Kubra Bugdayli2, Cynthia S. Crowson3, Margot S. Peters4, Lisa A. Drage5, Julia S. Lehman4 and Vaidehi Chowdhary6, 1Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 2Department of Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 3Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, 4Pathology and Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 5Dermatology, Mayo Clinic College of Medicine and Science, Rochester, MN, MN, 6Internal Medicine, Division of Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Eosinophilic Fasciitis (Shulman's Disease)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Eosinophilic fasciitis (EF) is a rare disease and there have been few published series that include clinical, pathological and serological data. These studies have provided disparate information on clinical course, with high rates of complete resolution and recurrence reported. Furthermore, no clear direction has emerged on the prognostic significance of features initially reported to be characteristic for EF.

Methods: We conducted a retrospective review of all EF patients evaluated at our institution from 1/1/1997 to 12/30/2016. Clinical records were reviewed to confirm the diagnosis of EF. Baseline demographic data, clinical, laboratory features at time of diagnosis and information on clinical course were collected. Kaplan-Meier methods were used to determine response and recurrence rates over time.

Results: We identified 83 patients with eosinophilic fasciitis seen within the study period. The median age of diagnosis was 53 years and the female to male ratio was 1:1. Majority of patients (90%) were diagnosed with combination of clinical features and biopsy, 6 (7%) were diagnosed based on clinical presentation alone, and 2 were diagnosed by clinical and imaging (MRI) features. Mean time to diagnosis from symptom onset was 7.9 months (range 1 – 45). Twenty-one patients (25%) reported exercise as a possible trigger. Groove sign was noted in only 24 (29%). Active inflammatory arthritis was noted in 9 patients at the time of initial EF evaluation, and only one of these had a known diagnosis of rheumatoid arthritis. Muscle weakness was described in 8 (10%), and EMG was interpreted as indicative of inflammatory myopathy in 6/17 (35%). The median absolute eosinophil count was 0.4-X 109/ml and peripheral eosinophilia was noted in 37/74 patients (50%). Elevated erythrocyte sedimentation rate was seen in 16/70 (23%) and elevated CRP in 33/56 (59%). CK was elevated in 2/40 (5%), but aldolase was elevated in 9/33 (27%). High titer (≥1:320 or ≥ 3 units by ELISA) positive ANA was seen in 5/66 (8%). The median follow up was 2.3 years (range 0.2 – 18.5) among 46 patients with at least one follow up visit. Of those, 35 were initially seen within 1 year of diagnosis, and were included in prognosis analysis. By 3 years, 57% (95% confidence interval [CI] 32 -73%) had achieved a complete response with resolution of skin thickening. The rate of recurrence was 47% (95% CI 20 – 65%) at 3 years.

Conclusion: In a cohort of patients with EF defined by clinical diagnosis, rates of classic features in addition to, complete response and recurrence rates, are similar to those in previously published reports. To our knowledge, this is the largest retrospective cohort study of patients with EF.


Disclosure: R. L. Mango, None; K. Bugdayli, None; C. S. Crowson, None; M. S. Peters, None; L. A. Drage, None; J. S. Lehman, None; V. Chowdhary, None.

To cite this abstract in AMA style:

Mango RL, Bugdayli K, Crowson CS, Peters MS, Drage LA, Lehman JS, Chowdhary V. Eosinophilic Fasciitis:  Baseline Retrospective Evaluation of Clinical Characteristics and Prognosis in a Cohort of 83 Patients [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/eosinophilic-fasciitis-baseline-retrospective-evaluation-of-clinical-characteristics-and-prognosis-in-a-cohort-of-83-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/eosinophilic-fasciitis-baseline-retrospective-evaluation-of-clinical-characteristics-and-prognosis-in-a-cohort-of-83-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology